Compare
Amgen vs Ligand Pharmaceuticals (AMGN vs LGND)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Ligand Pharmaceuticals (LGND) +60.8%; so far this year the figures are +40.7% and +62.0%.
Amgen is the larger company by market value, about 40.7 times the size of Ligand Pharmaceuticals.
On trailing earnings, AMGN trades at 26.7 times and LGND at 133.1 times.
Revenue grew +8.2% at AMGN and +1.0% at LGND over the last year.
AMGN yields 2.16%. LGND pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | LGND | |
|---|---|---|
| Price | $460.42 | $306.20 |
| 1-day | +0.03% | +2.41% |
| YTD | +40.67% | +61.95% |
| 1 year | +43.94% | +60.84% |
| 3 years | +76.51% | +474.48% |
| Market cap | $249.1B | $6.1B |
| P/E | 26.7 | 133.1 |
| P/S | 6.40 | 24.13 |
| P/B | 17.35 | 6.37 |
| Revenue growth | +8.20% | +1.00% |
| EPS growth | +33.30% | +13.30% |
| Gross margin % | 70.9 | 96.6 |
| Net margin % | 24.1 | 20.3 |
| ROE % | 65.4 | 5.4 |
| Debt / equity | 3.76 | 1.17 |
| FCF yield % | 3.8 | 1.5 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.85 |
| RSI (14) | 60.5 | 50.1 |
| Technical rating |